✦ LIBER ✦

The Cyclophilin Inhibitor Debio-025 is a Potent Inhibitor of Hepatitis C Virus Replication in vitro With a Unique Resistance Profile

✍ Scribed by Lotte Coelmont; Jan Paeshuyse; Suzanne Kaptein; Inge Vliegen; Artur Kaul; Erik De Clercq; Brigitte Rosenwirth; Pietro Scalfaro; Raf Crabbé; Ralf Bartenschlager; Jean-Maurice Dumont; Johan Neyts

Book ID: 113457448
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 64 KB
Volume: 74
Category: Article
ISSN: 0166-3542
DOI: 10.1016/j.antiviral.2007.01.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The non-immunosuppressive cyclosporin DE

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

✍ Jan Paeshuyse; Artur Kaul; Erik De Clercq; Brigitte Rosenwirth; Jean-Maurice Dum 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 708 KB

Cyclosporin A (CsA) inhibits the in vitro replication of HCV subgenomic replicons. We here report on the potent anti-HCV activity of the non-immunosuppressive cyclosporin DEBIO-025. The 50% effective concentration for inhibition of HCV subgenomic replicon replication in Huh 5-2 cells (luciferase ass

The cyclophilin inhibitor Debio-025 show

The cyclophilin inhibitor Debio-025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

✍ Robert Flisiak; Andrzej Horban; Philippe Gallay; Michael Bobardt; Suganya Selvar 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 522 KB

Debio-025 is an oral cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus activity in vitro. Its effect on viral load as well as its influence on intracellular Cyp levels was investigated in a randomized, double-blind, placebo-controlled study. Mean hepatitis C viral load decreased signifi

In vitro Anti-hepatitis C Virus (HCV) Ac

In vitro Anti-hepatitis C Virus (HCV) Activities and Resistance Profile of Debio 025, A Non-immunosuppressive Cyclophilin Binding Molecule

✍ Lotte Coelmont; Philippe Gallay; Michael Bobardt; Suzanne Kaptein; Jan Paeshuyse 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 76 KB

In Vitro Activity and Resistance Profile

In Vitro Activity and Resistance Profile of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus

✍ Bilello, J. P.; Lallos, L. B.; McCarville, J. F.; La Colla, M.; Serra, I.; Chapr 📂 Article 📅 2014 🏛 American Society for Microbiology 🌐 English ⚖ 569 KB

The cyclophilin inhibitor Debio 025 comb

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

✍ Robert Flisiak; Saya V. Feinman; Maciej Jablkowski; Andrzej Horban; Wieslaw Kryc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 727 KB

The anti-hepatitis C virus (HCV) effect and safety of three different oral doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon-␣2a (PEG IFN-␣2a) were investigated in a multicenter, randomized, double-blind, placebo-controlled escalating dose-ranging phase II study i

[787] THE REDUCTION OF BOTH CYCLOPHILIN

[787] THE REDUCTION OF BOTH CYCLOPHILIN B AND HCV-RNA BY THE CYCLOPHILIN INHIBITOR DEBIO-025 CONFIRMS THE IMPORTANCE OF CYCLOPHILIN B FOR HCV REPLICATION IN MAN

✍ P. Gallav; R. Flisiak; A. Horban; C. Aeschlimann; J.M. Dutnont; H. Porchet; P. S 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 119 KB